Rockwell Medical Tops Q2 EPS View
Rockwell Medical (NASDAQ:RMTI), a key supplier of hemodialysis concentrates, released its second quarter 2025 earnings on August 14, 2025. The most notable development was a steep year-over-year revenue decline of 38% as the company absorbed the financial impact of its largest customer’s previously announced move to another supplier. Despite the topline drop, Rockwell Medical delivered a non-GAAP earnings per share of $(0.01), which was stronger than the estimated $(0.05). Revenue (GAAP) came in slightly below estimates, at $16.1 million against expectations for $16.33 million. The quarter showed early stabilization, with tight cost controls and new contract wins, but the path to fully replacing lost sales volume remains a central focus.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Rockwell Medical is a leading U.S.-based manufacturer and distributor of hemodialysis concentrates, which are specialized solutions required for kidney dialysis treatments. Its products are supplied to dialysis providers and hospitals domestically and through select distribution channels abroad. The company gained prominence by supplying major providers, including a longstanding relationship with DaVita, although this customer transitioned away in mid-2025.
Source Fool.com
